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Abstract
Background: Hyperhomocysteinemia is a risk factor for cognitive decline and dementia, including Alzheimer
disease (AD). Homocysteine (Hcy) is a sulfur-containing amino acid and metabolite of the methionine pathway.
The interrelated methionine, purine, and thymidylate cycles constitute the one-carbon metabolism that plays a
critical role in the synthesis of DNA, neurotransmitters, phospholipids, and myelin. In this study, we tested the
hypothesis that one-carbon metabolites beyond Hcy are relevant to cognitive function and cerebrospinal fluid
(CSF) measures of AD pathology in older adults.
Methods: Cross-sectional analysis was performed on matched CSF and plasma collected from 120 older
community-dwelling adults with (n = 72) or without (n = 48) cognitive impairment. Liquid chromatography-mass
spectrometry was performed to quantify one-carbon metabolites and their cofactors. Least absolute shrinkage and
selection operator (LASSO) regression was initially applied to clinical and biomarker measures that generate the
highest diagnostic accuracy of a priori-defined cognitive impairment (Clinical Dementia Rating-based) and AD
pathology (i.e., CSF tau phosphorylated at threonine 181 [p-tau181]/β-Amyloid 1–42 peptide chain [Aβ1–42] >0.0779) to
establish a reference benchmark. Two other LASSO-determined models were generated that included the one-carbon
metabolites in CSF and then plasma. Correlations of CSF and plasma one-carbon metabolites with CSF amyloid and
tau were explored. LASSO-determined models were stratified by apolipoprotein E (APOE) ε4 carrier status.
Results: The diagnostic accuracy of cognitive impairment for the reference model was 80.8% and included age, years
of education, Aβ1–42, tau, and p-tau181. A model including CSF cystathionine, methionine, S-adenosyl-L-homocysteine
(SAH), S-adenosylmethionine (SAM), serine, cysteine, and 5-methyltetrahydrofolate (5-MTHF) improved the diagnostic
accuracy to 87.4%. A second model derived from plasma included cystathionine, glycine, methionine, SAH, SAM, serine,
cysteine, and Hcy and reached a diagnostic accuracy of 87.5%. CSF SAH and 5-MTHF were associated with CSF tau and
p-tau181. Plasma one-carbon metabolites were able to diagnose subjects with a positive CSF profile of AD pathology
in APOE ε4 carriers.
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Conclusions: We observed significant improvements in the prediction of cognitive impairment by adding one-carbon
metabolites. This is partially explained by associations with CSF tau and p-tau181, suggesting a role for
one-carbon metabolism in the aggregation of tau and neuronal injury. These metabolites may be particularly
critical in APOE ε4 carriers.
Keywords: Alzheimer’s disease, Cognition, CSF, Homocysteine, Metabolomics, One-carbon metabolism,
S-adenosyl-L-homocysteine, Tau
Background
The methionine, purine, and thymidylate cycles together
encompass one-carbon metabolism in the cytosol [1].
Both genetic (i.e., polymorphisms in MTHFR) and envir-
onmental factors influence one-carbon metabolism; how-
ever, genetic factors are thought to play a minor role,
whereas dietary intake of folate, vitamin B6, and vitamin
B12 explains 35% of the variation [2].
The most-studied biomarker of one-carbon metabolism
is homocysteine (Hcy), a sulfur-containing amino acid
generated by the metabolism of methionine [3]. Inherited
deficiencies in cystathionine synthase, methionine syn-
thase, or methylene-tetrahydrofolate reductase enzymes
causing homocystinuria and severe atherosclerotic plaques
were discovered in children in the mid-20th century [4].
More recently, hyperhomocysteinemia has been identified
as a risk factor for a multitude of conditions, including
cognitive decline and Alzheimer dementia [5–10]. Ele-
vated plasma Hcy is linked with deficiency in vitamins B6,
B12, and folate, as well as oxidative damage [11, 12].
However, Hcy-lowering trials with B vitamins have met
with mixed results that have dampened enthusiasm for
targeting Hcy in the prevention of cognitive decline or
Alzheimer disease (AD) progression [13]. There may be
several explanations for this inconsistency, but one often
overlooked is that emphasis on Hcy specifically may be in-
sufficient in magnitude of effect under the constraints of
current clinical trial designs. A role for other participants
in the one-carbon cycle that are highly interactive with
Hcy may have been underappreciated. For example, S-
adenosylmethionine (SAM), S-adenosyl-L-homocysteine
(SAH), and 5-methyltetrahydrofolate (5-MTHF) balance
may operate on several mechanisms that support cogni-
tive function, ranging from epigenetic modulation of
synaptic function in the hippocampus to methylation reac-
tions in the liver that convert phosphatidylethanolamine
to phosphatidylcholine and facilitate the delivery of essen-
tial fatty acids (i.e., docosahexaenoic acid) to the plasma
and the brain [14–18].
The ε4 allele of apolipoprotein E (APOE) gene is a
well-known and major genetic risk factor for AD [19].
Several recent studies have shown the interaction of
APOE genotype and environmental factors, such as diet,
on the risk of dementia and AD [20]. Nutrient intake
effect on cognitive function might be influenced by
APOE status, and the association between B12 and cog-
nitive function was indeed shown to be stronger in
APOE ε4 carriers [21]. The effects of vitamin B12 and
Hcy on gray matter volume may also be influenced by
APOE genotype in AD [22]. The clear interaction be-
tween Hcy, its cofactors, and APOE remains to be
more broadly investigated.
Metabolomics is an approach with the potential to
target and identify perturbations in specific pathways of
interest by quantifying a wide range of biochemical
compounds in tissue [23]. We leveraged this approach
to test the hypothesis that comprehensive assessment
of one-carbon metabolism in cerebrospinal fluid (CSF)
and plasma would better explain cognitive impairment
and CSF measures of AD pathology in older adults.
Methods
Study population
The participants with cognitive impairment were recruited
among outpatients who were referred to the memory
clinics, departments of psychiatry, and the Leenaards
Memory Center, Department of Clinical Neurosciences,
University Hospitals of Lausanne (Switzerland). Cogni-
tively intact participants were recruited from the commu-
nity through advertisement or among the spouses of
memory clinic patients. In total, 120 subjects were en-
rolled in the biomarker study.
CSF and plasma sample collection
Venous and lumbar punctures were performed between
8:30 and 9:30 a.m. after overnight fasting. For lumbar
puncture, a standardized technique with a 22-gauge
“atraumatic” spinal needle and the subject in a sitting or
lying position was applied [24]. A volume of 10–12 ml of
CSF was collected in polypropylene tubes. CSF samples
were centrifuged, frozen in aliquots, and stored at
−80 °C before further use. Blood was drawn into ethyl-
enediaminetetraacetic acid-containing vacutainers. After
20–30 minutes on ice, the tubes were centrifuged. Plasma
samples were aliquoted in polypropylene tubes and stored
at −80 °C.
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CSF β-amyloid 1–42 peptide chain, tau, tau phosphorylated
at threonine 181, and APOE ε4 genotyping
The measurements were performed using commercially
available enzyme-linked immunosorbent assay kits and
TaqMan assays (Applied Biosystems, Foster City, CA,
USA) as described in Additional file 1: Supplementary
Methods.
Targeted metabolomics of one-carbon metabolism
Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) was performed to measure absolute concentra-
tions of metabolites and cofactors of one-carbon metab-
olism in CSF and blood plasma as described previously
[23] (see Additional file 1: Supplementary Methods).
Primary outcome measures
Cognitive impairment
Diagnosis of mild cognitive impairment (MCI) or de-
mentia was based on neuropsychological and clinical
evaluation and made by a consensus conference of psy-
chiatrists and/or neurologists and neuropsychologists
prior to subject inclusion. The participants had no major
psychiatric or neurological disorders, nor did they have
substance abuse or severe or unstable physical illness
that might contribute to cognitive impairment. Magnetic
resonance imaging and computed tomographic scans
were used to exclude cerebral pathologies possibly inter-
fering with the cognitive performance. Subjects known
to take folate and B-vitamin supplementation were ex-
cluded from the study. MCI was diagnosed according to
widely used consensus recommendations [25]. Subjects
with MCI had memory impairment [26] and/or impair-
ment in another cognitive domain such as executive
tasks, as well as a Clinical Dementia Rating (CDR) [27]
score of 0.5. The diagnosis of probable AD dementia
was defined according to the clinical diagnostic criteria
for probable dementia due to AD according to the rec-
ommendations of the National Institute on Aging and
the Alzheimer’s Association [28] as well as the criteria of
the Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition, for dementia of the Alzheimer type
[29] with a CDR of 1. In the present study, we had only
nine subjects with AD. Because there is a clinical con-
tinuum between MCI and mild dementia, and because
the participants with cognitive impairment were patients
from memory clinics recruited in the same way regard-
less of MCI or mild dementia classification, these sub-
jects were collapsed with the MCI group and labeled as
cognitively impaired. The participants without cognitive
impairment had no history or evidence of cognitive
deficits and required a CDR of 0. We therefore defined
two categories of subjects on the basis of their CDR (i.e.,
CDR 0 or >0 [i.e., 0.5 or 1]) (Table 1).
CSF profiles of AD pathology
Subjects were also classified into two groups on the
basis of their CSF tau phosphorylated at threonine 181
(p-tau181)/β-amyloid 1–42 peptide chain (Aβ1–42) ra-
tio: “low” when p-tau181/Aβ1–42 was ≤0.0779 or “high”
when p-tau181/Aβ1–42 was >0.0779, considered as
negative and positive CSF profiles of AD pathology, re-
spectively. This threshold optimized the Youden index
[30] of the receiver operating characteristic (ROC)
curve for the prediction of CDR categories (CDR 0 ver-
sus CDR >0) [31]. It was similar to previously reported
findings [32]. Forty-two and 78 patients had positive and
negative CSF profiles of AD pathology, respectively.
Biomarker quality control
Metabolites with >5% missingness or below limits of
quantification were excluded, which left eight CSF and
plasma metabolites (Table 1). Data were log10-trans-
formed to tend toward a Gaussian distribution and stan-
dardized to null average and SD of 1 prior to statistical
analyses. One low-quality CSF sample was not analyzed.
CSF and plasma metabolite data were available for 119
and 120 subjects, respectively.
Statistical analyses
Using least absolute shrinkage and selection operator
(LASSO) logistic regression [33], we selected bio-
markers predict both cognitive impairment and CSF
profiles of AD pathology. A reference model was ini-
tially generated, testing variables that are likely to be
available to the clinician and known risk factors for AD
to provide a benchmark for comparison with the
models that included one-carbon metabolites. These in-
puts included age, sex, years of education, presence of
APOE ε4 allele, CSF Aβ1–42, CSF tau, and CSF p-tau181
concentrations for the prediction of cognitive impair-
ment; and age, sex, years of education, and presence of
APOE ε4 allele for the prediction of AD CSF profiles.
In addition to all variables used to make the reference
models, all metabolite measurements and CSF albumin
index were then included in building so-called best
models. The best models were built using LASSO re-
gression by entering the CSF and plasma metabolites
separately, thereby producing the two best models. A
tenfold cross-validation process was performed for each
LASSO analysis using the glmnet package in R [34],
which allows estimating the confidence interval (CI) of
the misclassification error for each value of the
regularization parameter λ. The LASSO analyses were re-
peated 100 times (1000 times for the reference model).
The models that minimized the upper limit of the cross-
validated misclassification error CI across the 100 runs
were selected. Their performance was assessed by ROC
area under the curve (AUC) estimation using a bootstrap
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approach with 1000 iterations [35]. Results were com-
pared visually and formally tested for significance against
the reference model using ROC AUC [36] and accuracy
using the McNemar test.
Two-sided correlation analyses between metabolites
and CSF Aβ1–42, tau, and p-tau181 were performed with
Pearson’s statistics and Bonferroni-corrected for multiple
comparisons. Significant correlations between the me-
tabolites and cofactors (p < 0.05) with CSF tau or p-
tau181 were studied further in a linear regression model
with tau or p-tau181 as the dependent variable and the
following explanatory covariates: each metabolite, age,
sex, APOE genotype (presence versus absence of an
APOE ε4 allele), CDR (0 versus >0), and CSF albumin
index (only for plasma metabolites). Values of the regres-
sion terms were reported, and their differences from 0 were
assessed with t tests. Interaction terms between the meta-
bolites and age, sex, CDR, or APOE genotype were identified
in a type II analysis of variance (ANOVA) with an F test.
Results
Demographic and clinical characteristics of the study
population
The cognitively impaired subjects were older and less
educated and had a higher prevalence of the APOE ε4
genotype than the cognitively intact group (CDR 0)
(Table 1). CSF Aβ1–42 was lower and CSF tau, CSF p-
tau181, CSF p-tau181/Aβ1–42, and CSF albumin index
Table 1 Demographics and clinical characteristics
All (n = 120) Cognitively normal
(CDR 0) (n = 48)
Cognitively impaired
(CDR 0.5 or 1) (n = 72)
Age, years 70.4 (7.9) 66.0 (7.4) 73.3 (6.9)a
Male sex, n (%) 43 (35.83%) 17 (35.42%) 26 (36.11%)
Education, years 12.4 (2.6) 13.2 (2.3) 11.8 (2.7)a
MMSE score, mean 26.9 (3.1) 28.5 (1.4) 25.9 (3.5)a
APOE ε4 carrier, n (%) 37 (30.83%) 11 (22.92%) 26 (36.11%)a
CSF parameters
Aβ1–42, pg/ml 847.4 (265.1) 957.4 (194.0) 774.0 (281.5)a
tau, pg/ml 371.3 (278.6) 221.5 (82.9) 471.1 (316.6)a
p-tau181, pg/ml 62.0 (35.2) 45.9 (13.3) 72.7 (40.9)a
p-tau181/Aβ1–42 0.088 (0.082) 0.049 (0.015) 0.114 (0.097)a
Albumin indexb 6.1 (2.4) 5.3 (1.9) 6.6 (2.5)a
Choline, μM 2.7 (0.5) 2.6 (0.4) 2.8 (0.6)a
Cystathionine, nM 35.8 (17.0) 34.4 (13.8) 36.7 (18.9)
Methionine, μM 3.6 (0.8) 3.3 (0.5) 3.9 (0.9)a
S-adenosylhomocysteine, nM 15.1 (5.8) 13.5 (4.3) 16.1 (6.3)a
S-adenosylmethionine, nM 183.0 (42.0) 188.2 (41.1) 179.4 (42.5)
Serine, μM 27.1 (4.7) 25.7 (4.1) 28.0 (4.8)a
Cysteine, μM 1.2 (0.4) 1.2 (0.4) 1.3 (0.4)
5-Methyltetrahydrofolate, nM 45.1 (12.5) 47.2 (10.9) 43.8 (13.4)
Plasma parameters
Cystathionine, nM 252.3 (232.4) 267.5 (290.0) 242.1 (185.9)
Glycine, μM 234.5 (60.6) 235.9 (59.7) 233.6 (61.5)
Methionine, μM 19.7 (3.6) 19.4 (2.9) 19.9 (4.1)
S-adenosylhomocysteine, nM 20.9 (9.1) 18.3 (6.3) 22.7 (10.2)a
S-adenosylmethionine, nM 71.9 (20.7) 67.6 (17.7) 74.7 (22.2)
Serine, μM 115.3 (19.9) 111.5 (16.9) 117.9 (21.3)
Cysteine, μM 158.3 (20.3) 150.7 (18.4) 163.3 (20.1)a
Homocysteine, μM 5.6 (1.6) 5.3 (1.5) 5.8 (1.7)
Abbreviations: Aβ β-Amyloid, APOE Apolipoprotein E, CDR Clinical Dementia Rating, CSF Cerebrospinal fluid, MMSE Mini Mental State Examination, p-tau181 Tau
phosphorylated at threonine 181
Data are given as means with SD within parentheses, unless indicated otherwise
aStatistically different (p ≤ 0.05) from CDR 0 using t tests for continuous variables and binomial proportion tests for categorical variables
bCSF albumin index = [CSF albumin]/[serum albumin] × 100
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were all higher in those with cognitive impairment. Con-
centrations of the one-carbon metabolites in CSF and
plasma are provided in Table 1.
Reference benchmark for the prediction of cognitive
impairment
The reference model for classification of cognitive impair-
ment included age, years of education, CSF Aβ1–42, CSF
tau, and CSF p-tau181 and produced a diagnostic accuracy
of 80.8% and an ROC AUC of 0.86 (95% CI 0.79–0.92).
This model classified 59 of 72 cognitively impaired subjects
correctly and 38 of 48 cognitively intact subjects correctly.
By comparison, a majority class prediction [37] produced a
diagnostic accuracy of about 60% to distinguish subjects
with CDR >0 from subjects with CDR 0.
CSF one-carbon metabolism and prediction of cognitive
impairment
After adding the CSF one-carbon metabolites, the diag-
nostic accuracy reached 87.4% (McNemar p value of
0.0704 compared with reference model), and the ROC
AUC reached 0.92 (CI 0.87–0.96) (p = 0.0732 versus the
reference model, as shown in Fig. 1a). The CSF metabo-
lites included cystathionine, methionine, SAH, SAM,
serine, cysteine, and 5-MTHF. Age, years of education,
CSF Aβ1–42, CSF tau, CSF p-tau181, and CSF albumin
index were also retained in the best model.
To evaluate the individual contribution of each me-
tabolite selected in the best models, we conducted
group comparisons for each metabolite. CSF methio-
nine and serine were higher in cognitive impairment,
with p values of 5.5 × 10−6 and 5.5 × 10−3, respectively
(Table 1 and Additional file 1: Figure S1). We also ex-
plored other CSF metabolites not chosen in the best
model and observed CSF SAH (p = 8.8 × 10−3) and choline
(p = 0.01) elevation in the cognitively impaired patients.
Plasma one-carbon metabolism and prediction of
cognitive impairment
After adding the plasma one-carbon metabolites in the
prediction of cognitive impairment, the diagnostic ac-
curacy reached 87.5% (McNemar p value of 0.0614),
and the ROC AUC was improved to 0.91 (CI 0.86–
0.96) (p = 0.0028 versus the reference model, as shown
in Fig. 1b). The best model included plasma cystathio-
nine, glycine, methionine, SAH, SAM, serine, cysteine,
and Hcy. Age, sex, years of education, presence of
APOE ε4 allele, CSF Aβ1–42, CSF tau, CSF p-tau181,
and CSF albumin index were in this best model. Plasma
cysteine and SAH were elevated in cognitively impaired
individuals, with p values of 5.5 × 10−4 and 4.6 × 10−3,
respectively (Table 1 and Additional file 1: Figure S2).
Reference benchmark for prediction of CSF profile of AD
pathology
The reference model for classification of the CSF profile
of AD pathology included age and presence of APOE ε4
allele. It had a diagnostic accuracy of 78.3% and an ROC
AUC of 0.83 (CI 0.74–0.90). A majority class prediction
produced a diagnostic accuracy of about 65% to distin-
guish subjects with p-tau181/Aβ1–42 ≤ 0.0779 from sub-
jects with p-tau181/Aβ1–42 > 0.0779.
Fig. 1 ROC curves of the (a) cerebrospinal fluid (CSF) and (b) plasma models predictive of cognitive impairment (Clinical Dementia Rating [CDR] 0
or >0). The CSF model includes cystathionine, methionine, S-adenosyl-L-homocysteine (SAH), S-adenosylmethionine (SAM), serine, cysteine, and
5-methyltetrahydrofolate (5-MTHF) in addition to age, years of education, CSF β-amyloid 1–42 peptide chain (Aβ1–42), CSF tau, CSF tau phosphorylated
at threonine 181 (p-tau181), and CSF albumin index. The plasma model includes cystathionine, glycine, methionine, SAH, SAM, serine, cysteine, and
homocysteine (Hcy) in addition to age, sex, years of education, presence of apolipoprotein E (APOE) ε4 allele, CSF Aβ1–42, CSF tau, CSF p-tau181, and
CSF albumin index. The ROC curves of the least absolute shrinkage and selection operator (LASSO) models including metabolites (in red) are compared
with the ROC curves of the reference LASSO models (in blue). The reference model is composed of age, years of education, CSF Aβ1–42, CSF tau, and
CSF p-tau181. The opacity of the curves is proportional to the accuracy of the models. The diamonds indicate the selected most accurate models. The
p values on the graphs indicate the significance of the differences of AUC. APOE Apolipoprotein E, HCY Homocysteine, 5-MTHF 5-Methyltetrahydrofolate,
SAH S-adenosyl-L-homocysteine, SAM S-adenosylmethionine
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CSF and plasma one-carbon metabolism and prediction
of CSF profile of AD pathology
CSF and plasma one-carbon metabolites were both
unable to improve the classification of CSF profile of
AD pathology beyond the reference model (data not
shown).
One-carbon metabolites and AD pathology
CSF levels of Aβ1–42, tau, and p-tau181 were signifi-
cantly different between CDR categories (Table 1). The
correlations of individual metabolite levels in CSF and
plasma with those markers of AD pathology were
therefore assessed. None of the one-carbon metabolites
correlated with CSF Aβ1–42. On the contrary, CSF cysta-
thionine, SAH, and 5-MTHF as well as plasma Hcy were
correlated with CSF p-tau181 (Fig. 2a). CSF SAH and 5-
MTHF were significantly associated with CSF tau
(Fig. 2b). CSF 5-MTHF was inversely correlated with
both CSF p-tau181 and tau (Fig. 2).
Metabolites significantly correlated with CSF p-tau181
or CSF tau were studied further in a linear regression
model. The coefficients of each regression term and
their significance are summarized in Table 2 for p-
tau181 and tau. The cognitive impairment status term
(CDR 0 versus CDR >0) was found to be associated in
all models, confirming the association of high levels of
CSF tau and CSF p-tau181 with cognitive impairment.
Interaction terms between metabolite biomarkers and
age, sex, CDR, and APOE ε4 genotype were then added
to the regression models and tested by ANOVA
(Table 3). An interaction was observed for CSF p-tau181
between plasma Hcy and APOE ε4 genotype (Fig. 3a).
For CSF p-tau181, significant interactions were also ob-
tained between SAH and 5-MTHF in CSF and APOE ε4
genotype. Sex was found to interact with CSF SAH and
plasma Hcy for CSF p-tau181 and with CSF SAH for
CSF tau.
Interaction of APOE ε4 genotype in one-carbon
metabolite-based prediction of AD pathology
Because we observed some metabolite interactions with
APOE genotype, we stratified the analysis on the basis of
individuals carrying the APOE ε4 allele (n = 37). In this
subgroup, no correlation was found with CSF levels of
Aβ1–42 and individual metabolite levels in both CSF and
plasma. Cystathionine, SAH, and 5-MTHF in CSF, as
well as Hcy in plasma, showed significant correlations
with CSF p-tau181 (Additional file 1: Figure S3a).
Concentrations of SAH and 5-MTHF in CSF and Hcy in
plasma were significantly associated with CSF tau
(Additional file 1: Figure S3b). Again, however, except
for cognitive impairment status (CDR 0 versus CDR >0),
these observed correlations were not impacted by other
clinical covariates (data not shown).
The metabolite measurements were considered in a
LASSO logistic regression to classify patients with non-
AD versus AD CSF profiles in this subgroup of individ-
uals. A reference LASSO logistic regression on known
or probable contributing variables (i.e., age and years of
education) provided a reference model with an accuracy
of 83.8% and an ROC AUC of 0.76 (CI 0.55–0.92). Here,
a majority class classifier provided 64.9% diagnostic ac-
curacy. Including metabolite markers measured in CSF
did not improve the ability to predict an AD biomarker
profile compared with the reference model. In contrast,
plasma metabolites provided nonsignificant improve-
ment in terms of accuracy but significantly increased
performance for AUC (Fig. 3b). The model with plasma
metabolites presented an accuracy of 89.2% (McNemar
p value of 0.6831) and an ROC AUC of 0.92 (CI 0.7–
1.00) (p = 0.0129 versus the reference model). Seven
Fig. 2 Cerebrospinal fluid (CSF) and plasma metabolites correlated with CSF tau phosphorylated at threonine 181 (p-tau181) (a) and CSF tau (b).
Concentration values were log10-transformed. Each dot represents a subject. The black line represents the linear fit, and the gray shading represents its
confidence interval. HCY Homocysteine, 5-MTHF 5-Methyltetrahydrofolate, SAH S-adenosyl-L-homocysteine, SAM S-adenosylmethionine
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Table 2 Regression coefficients in linear model with cerebrospinal fluid tau phosphorylated at threonine 181 and tau as dependent
variables
Regression term CSF cystathionine CSF SAH CSF 5-MTHF Plasma Hcy
CSF p-tau181
Intercept 1.0719a 1.0503a 2.1744a 1.1802a
Age 0.0063b 0.0038 0.0045c 0.0054c
Sexd −0.0279 −0.0223 −0.0140 −0.0236
APOE ε4 genotypee 0.0328 0.0195 0.0362 0.0314
CDR categoryf 0.1173b 0.1182b 0.1110b 0.1186b
Biomarker 0.1120 0.3195b −0.4965a 0.1670
CSF tau
Intercept 1.4134a 2.8174a
Age 0.0073c 0.0080c
Sexd −0.0215 −0.0108
APOE ε4 genotypee 0.0692 0.0894
CDR categoryf 0.1758a 0.1665b
Biomarker 0.3803b −0.6269a
Abbreviations: Aβ β-Amyloid, APOE Apolipoprotein E, CDR Clinical Dementia Rating, CSF Cerebrospinal fluid, Hcy Homocysteine, 5-MTHF 5-Methyltetrahydrofolate,
p-tau181 Tau phosphorylated at threonine 181, SAH S-adenosyl-L-homocysteine
Values of the regression terms are reported, and their differences from 0 were assessed with a t test
ap ≤ 0.001
bp ≤ 0.01
cp ≤ 0.05
dFemales (versus reference males)
eAPOE ε4 carriers (versus reference noncarriers)
f CDR >0 (versus reference CDR 0)
Table 3 Regression coefficients in linear model with cerebrospinal fluid tau phosphorylated at threonine 181 and tau as dependent
variables of interaction terms between biomarkers and different variables
Interaction term CSF cystathionine CSF SAH CSF 5-MTHF Plasma Hcy
CSF p-tau181
Age −0.0011 −0.0098 0.0036 0.0113
Sexa −0.0652 −0.4815b 0.3443 −0.6850b
APOE ε4 genotypec 0.2169 0.5126b −0.5687b 1.1427d
CDR categorye 0.1877 0.2122 −0.2434 0.2833
CSF tau
Age −0.0076 0.0099
Sexa −0.7407f 0.4541
APOE ε4 genotypec 0.4953 −0.6965
CDR categorye 0.1352 −0.2681
Abbreviations: APOE Apolipoprotein E, CDR Clinical Dementia Rating, CSF Cerebrospinal fluid, Hcy Homocysteine, 5-MTHF 5-Methyltetrahydrofolate, p-tau181 Tau
phosphorylated at threonine 181, SAH S-adenosyl-L-homocysteine
Every interaction was tested in separate models, with only one interaction per model. Values of the regression interaction terms are reported, and their difference
from 0 was assessed with an F test in analysis of variance
aFemales (versus reference males)
bp ≤ 0.05
cAPOE ε4 carriers (versus reference noncarriers)
dp ≤ 0.001
eCDR >0 (versus reference CDR 0)
fp ≤ 0.01
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plasma metabolites were included in this mathematical
model (i.e., glycine, methionine, SAH, SAM, serine, cysteine,
and Hcy) in addition to age, sex, years of education, and
CSF albumin index. Box plots of plasma metabolite mea-
surements for non-AD versus AD CSF profiles in APOE
ε4 carriers are provided in Additional file 1: Figure S4.
Discussion
In the present study, we deployed a LC-MS/MS-based
method to expand previous work [38], targeting one-
carbon metabolism in both CSF and plasma, and to
better understand its role in cognitive impairment and
AD pathology. We identified CSF and plasma profiles in-
cluding several one-carbon metabolites beyond Hcy as-
sociated with cognitive impairment in older adults. The
association between several CSF and plasma one-carbon
metabolites with CSF tau and p-tau181 warrants further
research. Although we were unable to predict an a
priori-stated CSF profile of AD pathology in the total co-
hort, the plasma one-carbon metabolites markedly im-
proved the classification of CSF profiles of AD pathology
in APOE ε4 carriers.
Our results highlight the contribution of methionine,
serine, choline, and cysteine in addition to the more
commonly assessed and reported one-carbon metabo-
lites (i.e., SAM, SAH, and Hcy). Methionine supplemen-
tation in wild-type mice can induce neurotoxicity, higher
levels of tau phosphorylation and Aβ peptides in the
brain, and memory loss [39]. These mechanisms may ex-
plain our observation of higher CSF methionine in cog-
nitive impairment. Protective effects of choline against
age-related cognitive deficits were previously evidenced
in animal models [40], and better memory performance
was related to a higher concurrent choline intake in a
large, nondemented, community-based human popula-
tion [41]. However, we observed higher CSF choline in
cognitive impairment, an inconsistency that may reflect
neurodegeneration and the breakdown of synaptic mem-
branes enriched with choline [42]. We showed signifi-
cantly increased CSF and plasma SAH in cognitive
impairment, which is consistent with previous findings
[14, 43].
Several metabolites of the one-carbon cycle measured
in CSF and plasma were associated with tau metabolism,
reflected by total tau and p-tau181 in the CSF, after con-
trolling for potential confounders. Higher CSF 5-MTHF
appeared protective, whereas higher CSF SAH appeared
to promote tau aggregation and neuronal injury. These
results are consistent with reports demonstrating higher
CSF SAH and lower CSF 5-MTHF associated with
higher CSF p-tau181 [14]. Accordingly, impairment of
the one-carbon metabolism, induced by feeding with a
high-methionine/low-folate diet, was shown to increase
SAH levels, downregulate methyltransferase, reduce pro-
tein phosphatase 2A methylation, and induce accumula-
tion of neurofibrillary tangle pathology in mice [44].
Higher levels of tau phosphorylation were also observed
in the brains of wild-type mice fed a methionine-enriched
diet, putatively inducing the fragmentation of tau from
microtubules and leading to fibrillization [39]. To-
gether, these results suggested that altered one-carbon
Fig. 3 Association of homocysteine (Hcy) levels measured in plasma
with cerebrospinal fluid (CSF) tau phosphorylated at threonine 181
(p-tau181), stratified by the presence of the apolipoprotein E (APOE)
ε4 allele (a). The correlation between expression levels of plasma
Hcy and CSF p-tau181 differs according to APOE genotype. ROC
curves of the models predictive of non-Alzheimer disease (non-AD)
versus AD CSF profiles (i.e., p-tau181/Aβ1–42≤ 0.0779 and p-tau181/
Aβ1–42 > 0.0779, respectively) (b). The ROC curves of the least absolute
shrinkage and selection operator (LASSO) models including metabolites
in plasma (in red) are compared with the ROC curves of the reference
LASSO models (in blue). The plasma model (in red) includes glycine,
methionine, S-adenosyl-L-homocysteine (SAH), S-adenosylmethionine
(SAM), serine, cysteine, and Hcy in addition to age, sex, years of
education, and CSF albumin index. The reference model (in blue)
includes age and years of education. The opacity of the curves is
proportional to the accuracy of the models. The diamonds indicate
the selected most accurate models. The p value on the graph indicates
the significance of the differences of AUC. APOE Apolipoprotein E, HCY
Homocysteine, SAH S-adenosyl-L-homocysteine, SAM S-adenosylmethionine
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metabolism may contribute to microtubule-associated
tau protein hyperphosphorylation and neurodegenera-
tion in general. Our inability to observe a relationship
between any one-carbon metabolites with CSF Aβ1–42
was remarkable and consistent with some studies [14, 45],
but in contradiction with other in vitro and in vivo pre-
clinical investigations [46, 47]. A recent study of human
adults with normal cognition found that disturbed one-
carbon metabolism may be related to increased CSF levels
of Aβ1–42 and soluble amyloid precursor protein forms,
suggesting a contribution to the accumulation of cerebral
amyloid pathology [48], making it difficult to draw conclu-
sions at this time.
We were unable to predict CSF profiles of AD path-
ology until an interaction with APOE genotype was iden-
tified. For example, whereas plasma Hcy appeared
insubstantial to CSF tau in the total sample, hyperhomo-
cysteinemia was relevant to CSF tau in the APOE ε4 car-
riers. This was further corroborated by our prediction of
positive AD pathology using the p-tau181/Aβ1–42 ratio
after restricting the analysis to APOE ε4 carriers only.
Although this interaction between Hcy, APOE, and tau
pathology was clear in our analysis, the biological ration-
ale behind this interaction is less clear. A recent report
demonstrated that plasma Hcy predicts the conversion
from MCI to AD only in APOE ε4 carriers [49], adding a
further level of consistency to our findings. Other me-
tabolites of the one-carbon cycle, such as CSF SAM
[50], may also be more relevant in APOE ε4 carriers and
should be further explored.
Taken together, our results show that one-carbon
metabolism is relevant to cognition independent of and
beyond AD core pathology. One-carbon metabolism dis-
turbances may cripple DNA repair, methylation, and/or
synthesis, as well as reduce the availability of neuro-
transmitters, phospholipids, and myelin [51]. Several of
these mechanisms may be involved in cognitive dysfunc-
tion and underlying neurobiology.
The present study has limitations. We used measures
of cognition and CSF measures of AD in a cross-
sectional analysis, and the temporality of the associations
cannot be extrapolated. Nevertheless, we present the
most comprehensive mapping of the one-carbon path-
way in both CSF and plasma in older adults. The results
are encouraging and in the future should be replicated
in an independent cohort as well as confirmed in rela-
tion to longitudinal change in cognition and the inci-
dence of AD.
Conclusions
Our results suggest that several one-carbon metabolites
beyond Hcy are relevant to AD pathology and cognitive
function in older adults. This may partially explain why
Hcy-lowering trials have been mostly disappointing and
opens the possibility that other metabolites in the
pathway may also be relevant targets for the preven-
tion of cognitive decline and the underlying neuro-
biology of AD.
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Additional file 1: Figure S1. Box plots of CSF metabolite
measurements for CDR of 0 and CDR >0 (i.e., CDR 0.5 or 1). Level of
significance is indicated as p value after Bonferroni correction. Values were log-
transformed. Figure S2. Box plots of plasma metabolite measurements for
CDR 0 and CDR >0 (i.e., CDR 0.5 or 1). Level of significance is indicated as p
value after Bonferroni correction. Concentration values were log-transformed.
Figure S3. CSF and plasma metabolites correlated with CSF p-tau181 (a)
and CSF tau (b) in APOE ε4 carriers (n = 37). Concentration values were
log-transformed. Each dot represents a subject. The black line represents the
linear fit, and the gray shading represents its confidence interval. Figure S4.
Box plots of plasma metabolite measurements in APOE ε4 carriers (n = 37)
according to CSF p-tau181/Aβ1–42 ratio (i.e., “low” when p-tau181/Aβ1–42 is
≤0.0779 and “high” when p-tau181/Aβ1–42 is > 0.0779) for negative and
positive CSF profiles of AD pathology, respectively. Concentration values were
log10-transformed. Level of significance is indicated as p value after Bonferroni
correction. Supplementary Methods. (PDF 831 kb)
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